Elicio Therapeutics (ELTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Elicio Therapeutics (ELTX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.08 of bullish evidence against -0.37 bearish.

Elicio Therapeutics last closed at $1.92, +0.00% on the session.

Against the IVW growth benchmark the position is -0.92% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

16 graded predictions for ELTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Elicio Therapeutics in the 1st percentile on return on equity, where 100 is best.

Elicio Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $50.46M.

StockMap tracks Elicio Therapeutics as the 285th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Elicio Therapeutics ranks 285th of 344 in the group, against a group median of -0.21.